share_log

Advanced Health Intelligence Signs Letter of Intent to Develop and Deploy a Digital Underwriting Solution For the Insurance Industry

Advanced Health Intelligence Signs Letter of Intent to Develop and Deploy a Digital Underwriting Solution For the Insurance Industry

Advanced Health Intelligence簽署意向書,爲保險業開發和部署數字承保解決方案
newsfile ·  2023/09/20 06:58

Highlights

亮點

  • AHI signs a letter of Intent with Unisure.
  • AHI與聯合國教科文組織簽署了意向書。
  • SCOR (SCR.FP) and Unisure to collaborate with AHI.
  • SCOR(SCR.FP)和安康與AHI合作。
  • SCOR is one of the world's largest Reinsurers.
  • SCOR是世界上最大的再保險公司之一。
  • AHI will deploy a digital underwriting capability using AHI's Biometric Health Assessment.
  • AHI將使用AHI的生物識別健康評估部署數位承保能力。
  • AHI is to Digitise phenotypical Biometric data for insurance underwriting purposes.
  • AHI將把表型生物識別數據數位化,用於保險承保目的。

South Perth, Australia--(Newsfile Corp. - September 20, 2023) - Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ("AHI" or "the Company") is pleased to inform shareholders that the Company has entered a Letter of Intent (LOI) with UK-based Unisure Group to design, develop and deploy the AHI Biometric Health Assessment (BHA).

澳大利亞南珀斯-(Newsfile Corp.-2023年9月20日)-先進健康智慧有限公司 (ASX:ahi)(納斯達克:ahi)(“ahi”或“公司”)我們很高興地通知股東,公司已經與總部位於英國的安康集團簽署了一份意向書,以設計、開發和部署AHI生物識別健康評估(BHA)。

The LOI is a result of exploratory discussions between AHI, SCOR and Unisure over several months, resulting in SCOR partnering with Unisure to develop and deploy the digital application with AHI.

意向書是AHI、SCOR和聯合國休閒中心幾個月來探索性討論的結果,導致SCOR與聯合國休閒中心合作開發和部署與AHI的數位應用程式。

Unisure and AHI have executed a Letter of Intent to develop and deploy a world-first digital underwriting solution utilising AHI's revolutionary smartphone-based biometric health risk assessment. The intent of the relationship is to create a series of innovative insurance offerings by leveraging AHI's technology with SCOR's wealth of Reinsurance knowledge to service the global retail insurance market. Partnering with Unisure and SCOR presents a unique opportunity that will utilise the proprietary AHI digital blood biomarkers and phenotypical data combined with insurers' rich actuarial and underwriting data to develop and design new digital underwriting solutions.

安康和AHI簽署了一份意向書,利用AHI革命性的基於智慧手機的生物識別健康風險評估,開發和部署全球首個數字承保解決方案。雙方合作的目的是通過利用AHI的技術和SCOR豐富的再保險知識來創建一系列創新的保險產品,為全球零售保險市場服務。與安康和SCOR的合作提供了一個獨特的機會,將利用專有的AHI數位血液生物標記物和表型數據,結合保險公司豐富的精算和承保數據來開發和設計新的數位承保解決方案。

The collaboration will result in SCOR and Unisure deploying AHI's technology to digitally assess the health risk across a minimum of 5,000 individuals as part of a health screening for insurance requirements.

這項合作將導致SCOR和聯合國休閒中心部署AHI的技術,以數位方式評估至少5000人的健康風險,作為保險要求健康篩查的一部分。

The intention is that this will be the first in a series of AHI's insurance market product developments to digitise risk underwriting, which can be used to augment traditional blood pathology underwriting over time. The breadth of AHI's 61 health outputs, resulting in 41 biometric captures across five major health and disease risk categories - cardio-respiratory, body composition, estimated blood biomarkers, metabolic health and mental health offers comprehensive insights for morbidity and mortality risk highly relevant to health and life policy pricing. AHI is in a distinctive position to work alongside insurers to cost-effectively unlock the large, unpenetrated, and un-serviced middle market where traditional medical underwriting is now deemed too slow and expensive.

其意圖是,這將是AHI將風險承保數位化的一系列保險市場產品開發中的第一個,隨著時間的推移,這種產品可用於增強傳統的血液病理承保。AHI的61項健康產出的廣度,產生了五個主要健康和疾病風險類別-心肺、身體成分、估計血液生物標記物、代謝健康和精神健康-的41個生物識別捕獲,提供了與健康和人壽保險定價高度相關的發病率和死亡率風險的全面洞察。AHI處於一個獨特的地位,可以與保險公司合作,以經濟高效的方式打開龐大的、未被滲透和未得到服務的中端市場,在這個市場上,傳統的醫療承保現在被認為過於緩慢和昂貴。

Dylan Garnett, Chief Innovation Officer at AHI, said:

AHI首席創新官迪倫·加內特表示:

"With more than two decades of experience in the insurance industry, I've witnessed its evolution, particularly the growing need for digital transformation in insurance underwriting. This transition is to deliver a more cost-effective and precise approach to assessing the appropriate coverage for individuals. Unisure is an ideal collaborator for the initial implementation of the BHA underwriting solution. We will launch the program involving a minimum of 5,000 participants, which will be crucial learnings in providing us with feedback and helping us shape the perfect product offering for the market. We value these participants immensely, as they represent a manageable segment for our solution's iterative development and refining.

憑藉在保險業二十多年的經驗,我親眼目睹了保險行業的發展,特別是保險承保領域對數字化轉型的日益增長的需求。這種轉變是為了提供一種更具成本效益和精確度的方法來評估個人的適當保險範圍。對於BHA承保解決方案的初始實施來說,Unseing是一個理想的合作夥伴。我們將啟動該計劃,至少有5000名參與者參與,這將是為我們提供反饋和幫助我們為市場塑造完美產品產品的關鍵學習。我們非常重視這些參與者,因為他們代表著我們解決方案迭代開發和完善的可管理部分。

AHI and SCOR, as partners, align perfectly with our philosophy and demonstrate a robust commitment to their clients. SCOR is a particularly suitable partner for AHI due to their client-centric approach. They customise their reinsurance solutions to meet their client's individual needs and risk profiles. SCOR's experienced underwriters and risk analysts work in close collaboration with clients to create comprehensive yet cost-effective risk strategies. This shared philosophy will be instrumental in our success as we move forward."

AHI和SCOR作為合作夥伴,與我們的理念完美地結合在一起,並展示了對客戶的堅定承諾。SCOR是AHI特別合適的合作夥伴,因為他們以客戶為中心。他們定製他們的再保險解決方案,以滿足客戶的個人需求和風險狀況。SCOR的經驗豐富的承銷商和風險分析師與客戶密切合作,制定全面而具成本效益的風險策略。在我們前進的過程中,這種共同的理念將有助於我們取得成功。“

Vlado Bosanac, AHI Founder and Head of Strategy, said:

AHI創始人兼戰略主管弗拉多·博薩納克表示:

"This Letter of Intent (LOI) brings a significant partnership to AHI with SCOR and Unisure Group. The collaboration signifies a major milestone in our journey to demonstrate to the insurance industry the powerful data AHI delivers to assist the industry in better understanding their policyholders, their health and the appropriate coverage they need. By leveraging AHI's innovative technology with the industry knowledge brought by SCOR and Unisure's expertise, we are poised to create a world-first on-device biometric digital underwriting solution. This partnership enhances our industry understanding of digital insurance tools and positions AHI at the forefront of the digital insurance revolution, unlocking cost-effective solutions for the unpenetrated middle market."

這份意向書(LOI)為AHI與SCOR和康樂集團帶來了重要的合作夥伴關係。這項合作標誌著我們向保險業展示AHI提供的強大數據以幫助保險業更好地瞭解其保險契約者、他們的健康和他們所需的適當保險的旅程中的一個重要里程碑。通過利用AHI的創新技術和SCOR帶來的行業知識,以及安康的專業知識,我們準備創建世界首個設備上生物識別數位承保解決方案。這一合作關係增強了我們行業對數字保險工具的理解,並將AHI定位在數字保險革命的前沿,為未滲透的中間市場解鎖了高性價比的解決方案。

AHI anticipates that revenue generation through this agreement will commence upon the initial deployment of the solution. The Company will continuously update our shareholders regarding the progress leading up to and including the commercial launch.

AHI預計,通過這項協定產生的收入將從解決方案的初始部署開始。公司將不斷向我們的股東通報商業推出前的進展情況,包括商業推出的進展情況。

This announcement has been approved by the Chairman and CEO of Advanced Health Intelligence Ltd.

這一公告已得到Advanced Health Intelligence Ltd.董事長兼首席執行官的批准。

For more information, contact:

如需更多資訊,請聯繫:

Dylan Garnett
Chief Innovation Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

迪倫·加內特
首席創新官
先進健康智慧有限公司
電子郵箱:admin@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech

弗拉多·博薩納克
創始人/戰略主管
先進健康智慧有限公司
電子郵箱:admin@ahi.tech

About Unisure Group

關於康樂集團

Unisure is an international health and life insurance solutions provider with offices on four continents. They provide SMEs with Group Life and Disability and Group Business Protection insurance solutions, as well as personalised solutions for employers who have employees that travel across borders. Unisure also provides individuals with a range of international life insurance solutions. They have their own medical clinics in Zambia and offer International Private Medical Insurance solutions globally. They distribute their solutions through intermediaries, insurance brokers and financial advisers.

安康是一家國際健康和人壽保險解決方案提供商,在四大洲設有辦事處。他們為中小企業提供團體人壽和殘疾保險解決方案和團體商業保護保險解決方案,以及為有員工跨境旅行的僱主提供個性化解決方案。安康還為個人提供一系列國際人壽保險解決方案。他們在尚比亞擁有自己的醫療診所,並在全球提供國際私人醫療保險解決方案。他們通過中間人、保險經紀人和金融顧問分發他們的解決方案。

Unisure's vision is to be a loved and trusted global insurance provider, protecting one million families every year through dynamic, equitable, and fully portable insurance solutions.

安康的願景是成為一家受人喜愛和信賴的全球保險提供商,每年通過動態、公平和完全便攜的保險解決方案保護100萬個家庭。

For more information, visit and .

有關更多資訊,請訪問和。

About SCOR

關於SCOR

SCOR, a leading global reinsurer, offers its clients a diversified and innovative range of reinsurance and insurance solutions and services to control and manage risk. Applying "The Art & Science of Risk", SCOR uses its industry-recognized expertise and cutting-edge financial solutions to serve its clients and contribute to the welfare and resilience of society. SCOR offers its clients a Tier 1 reinsurer rating from Standard & Poor's, AM Best, Moody's and Fitch. The Group generated premiums of EUR 19.7 billion in 2022 and serves clients in more than 160 countries from its 35 offices worldwide. For more information, visit: .

SCOR是一家全球領先的再保險公司,為其客戶提供多元化和創新的再保險和保險解決方案及服務,以控制和管理風險。應用“風險的藝術與科學”,SCOR利用其行業公認的專業知識和尖端的金融解決方案為客戶服務,並為社會的福利和韌性做出貢獻。SCOR為其客戶提供來自標準普爾、AM Best、穆迪和惠譽的一級再保險公司評級。該集團在2022年創造了197億歐元的保費收入,並通過其全球35個辦事處為160多個國家和地區的客戶提供服務。有關更多資訊,請訪問:。

About Advanced Health Intelligence Ltd

關於先進健康智慧有限公司

Advanced Health Intelligence Ltd ('AHI') delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.

先進健康智慧有限公司(“AHI”)通過我們的專有技術和流程,為世界各地的醫療保健提供者、保險公司、僱主和政府機構提供可擴展的健康評估、風險分層和數字分診功能。

Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:

自2014年以來,AHI一直通過智慧手機提供健康科技創新,首先是世界上第一個設備上的人體尺寸測量功能。AHI開發了一項專利技術,通過一套元件化解決方案展示了數位化醫療的下一個前沿,最終實現了:

  • Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
  • Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
  • Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates.
  • On-device dermatological skin identification across 588 skin conditions across 133 categories (Inc. Melanoma); and
  • Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.
  • 身體尺寸和成分評估,以確定肥胖的共病,如糖尿病風險估計。
  • 血液生物標誌物預測,包括HbA1C、高密度脂蛋白、低密度脂蛋白和10年死亡風險。
  • 經皮光學成像返回生命體徵和心血管疾病風險評估。
  • 在133個類別的588種皮膚疾病(包括黑色素瘤)中進行設備上的皮膚科皮膚識別;以及
  • 協助合作夥伴提供個性化的治療性和非治療性健康指導,以改善日常習慣和培養健康素養。

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI's technology is at the forefront of innovation and the needs of our consumers.

我們由機器學習、人工智慧、電腦視覺和受過醫學培訓的數據科學家組成的世界級主題專家團隊確保了AHI的技術處於創新的前沿,並滿足了我們消費者的需求。

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.

憑藉對規模影響的關注,AHI自豪地展示了數位醫療轉型的這一裡程碑,提供了可在智慧手機上和通過智慧手機訪問的生物識別派生分診解決方案。有了這些先進的技術,AHI幫助其合作夥伴識別其消費者的風險,並將他們分流到正確的保健路徑,以便在人口規模上進行主動健康管理。

For more information, please visit:

如需更多資訊,請訪問:

Cautionary Note Regarding Forward-Looking Statements:

有關前瞻性陳述的注意事項:

This news release contains information or statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新聞稿包含構成“前瞻性陳述”的資訊或陳述。此類前瞻性表述涉及已知和未知的風險、不確定性和其他因素,可能導致實際結果、業績或成就或發展與此類前瞻性表述明示或暗示的預期結果、業績或成就大不相同。前瞻性陳述是指不是歷史事實的陳述,通常但並非總是通過“預期”、“計劃”、“預期”、“相信”、“打算”、“估計”、“專案”、“潛在”和類似的表述,或事件或條件“將”、“將”、“可能”、“可能”或“應該”發生等詞語來識別。

Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies, and outlook of Advance Health Intelligence, and includes statements about, among other things, future developments and the future operations, strengths, and strategies of Advance Health Intelligence. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

前瞻性資訊可能包括但不限於關於Advance Health Intelligence的運營、業務、財務狀況、預期財務結果、業績、前景、機會、優先事項、目標、目標、持續目標、里程碑、戰略和展望的陳述,還包括關於Advance Health Intelligence的未來發展和未來運營、優勢和戰略的陳述。提供前瞻性資訊的目的是提供有關管理層目前對未來的期望和計劃的資訊,請讀者注意,此類陳述可能不適用於其他目的。這些聲明不應被解讀為對未來業績或結果的保證。

The forward-looking statements made, or perceived to be made, in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analysis, and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavorable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Advanced Health Intelligence's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

本新聞稿中作出或被視為作出的前瞻性陳述是基於管理層的假設和分析以及管理層可能利用的其他因素,包括管理層對歷史趨勢、當前狀況和預期未來發展的經驗和評估,以得出結論並做出預測或預測。儘管管理層認為這些假設、分析和評估在作出本新聞稿中包含的陳述時是合理的,但實際結果可能與任何前瞻性陳述中所預測的大不相同。可能導致實際結果與前瞻性聲明大不相同的風險和因素包括:監管行動的時機和不可預測性;與其運營或業務有關的監管、立法、法律或其他事態發展;營銷和銷售能力有限;行業和產品開發的早期階段;有限的產品;對第三方的依賴;不利的宣傳或消費者看法;總體經濟狀況和金融市場;競爭加劇的影響;關鍵管理人員的流失;資本要求和流動性;獲得資本的機會;資本支出的時機和數額;新冠肺炎的影響;對先進健康智慧產品的需求和市場規模的變化;專利法改革;專利訴訟和知識產權;利益衝突;以及總體市場和經濟狀況。

The forward-looking information contained in this news release represents the expectations of Advance Health Intelligence as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Advance Health Intelligence undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

本新聞稿中包含的前瞻性資訊代表了截至本新聞稿發佈之日對Advance Health Intelligence的期望,因此,在該日期之後可能會發生變化。讀者不應過分重視前瞻性資訊,也不應依賴截至任何其他日期的這些資訊。Advance Health Intelligence沒有義務在管理層的信念、估計或意見或其他因素髮生變化時更新這些前瞻性陳述。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論